165 related articles for article (PubMed ID: 20618157)
1. ATTEMPTS system: a macromolecular prodrug strategy for cancer drug delivery.
Huang Y; Park YS; Wang J; Moon C; Kwon YM; Chung HS; Park YJ; Yang VC
Curr Pharm Des; 2010 Jul; 16(21):2369-76. PubMed ID: 20618157
[TBL] [Abstract][Full Text] [Related]
2. The ATTEMPTS delivery systems for macromolecular drugs.
Kwon YM; Li Y; Naik S; Liang JF; Huang Y; Park YJ; Yang VC
Expert Opin Drug Deliv; 2008 Nov; 5(11):1255-66. PubMed ID: 18976135
[TBL] [Abstract][Full Text] [Related]
3. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
Liang JF; Park YJ; Song H; Li YT; Yang VC
J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
[TBL] [Abstract][Full Text] [Related]
4. 15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting.
Ye J; Shin MC; Liang Q; He H; Yang VC
J Control Release; 2015 May; 205():58-69. PubMed ID: 25483423
[TBL] [Abstract][Full Text] [Related]
5. PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.
Shin MC; Zhang J; Min KA; He H; David AE; Huang Y; Yang VC
Pharm Res; 2015 Aug; 32(8):2690-703. PubMed ID: 25701313
[TBL] [Abstract][Full Text] [Related]
6. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects.
Park YJ; Liang JF; Song H; Li YT; Naik S; Yang VC
Adv Drug Deliv Rev; 2003 Feb; 55(2):251-65. PubMed ID: 12564979
[TBL] [Abstract][Full Text] [Related]
7. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
[TBL] [Abstract][Full Text] [Related]
8. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation.
Kwon YM; Li YT; Liang JF; Park YJ; Chang LC; Yang VC
J Control Release; 2008 Sep; 130(3):252-8. PubMed ID: 18652856
[TBL] [Abstract][Full Text] [Related]
9. Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy.
Wang H; Moon C; Shin MC; Wang Y; He H; Yang VC; Huang Y
Nanotheranostics; 2017; 1(1):114-130. PubMed ID: 29071181
[TBL] [Abstract][Full Text] [Related]
10. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
[TBL] [Abstract][Full Text] [Related]
11. Improved Protein Toxin Delivery Based on ATTEMPTS Systems.
Chen Y; Zhang M; Min KA; Wang H; Shin MC; Li F; Yang VC; Huang Y
Curr Drug Targets; 2018 Feb; 19(4):380-392. PubMed ID: 28260497
[TBL] [Abstract][Full Text] [Related]
12. A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct.
Song H; Liang JF; Yang VC
ASAIO J; 2000; 46(6):663-8. PubMed ID: 11110262
[TBL] [Abstract][Full Text] [Related]
13. Application of "ATTEMPTS" for drug delivery.
Naik SS; Liang JF; Park YJ; Lee WK; Yang VC
J Control Release; 2005 Jan; 101(1-3):35-45. PubMed ID: 15588892
[TBL] [Abstract][Full Text] [Related]
14. Macromolecular prodrugs based on synthetic polyaminoacids: drug delivery and drug targeting in antitumor therapy.
Cavallaro G; Pitarresi G; Giammona G
Curr Top Med Chem; 2011; 11(18):2382-9. PubMed ID: 21671863
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.
Liang JF; Li YT; Connell ME; Yang VC
AAPS PharmSci; 2000; 2(1):E7. PubMed ID: 11741223
[TBL] [Abstract][Full Text] [Related]
16. Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules.
Absar S; Nahar K; Choi S; Ahsan F; Yang VC; Kwon YM
J Biomed Mater Res A; 2014 Aug; 102(8):2481-90. PubMed ID: 23946132
[TBL] [Abstract][Full Text] [Related]
17. A macromolecular prodrug strategy for combinatorial drug delivery.
Li NN; Lin J; Gao D; Zhang LM
J Colloid Interface Sci; 2014 Mar; 417():301-9. PubMed ID: 24407691
[TBL] [Abstract][Full Text] [Related]
18. A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.
Yuan Z; Yi X; Zhang J; Cheng S; Zhuo R; Li F
Chem Commun (Camb); 2013 Jan; 49(8):801-3. PubMed ID: 23235958
[TBL] [Abstract][Full Text] [Related]
19. Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature.
Chen Y; Zhang M; Jin H; Tang Y; Wang H; Xu Q; Li Y; Li F; Huang Y
Biomaterials; 2017 Feb; 116():57-68. PubMed ID: 27914267
[TBL] [Abstract][Full Text] [Related]
20. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
Luo C; Sun J; Sun B; He Z
Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]